STAR 2009

1 Treatments

Studied treatment stent placement and medical treatment

Control treatment medical treatment alone (antihypertensive treatment, statin, aspirin)

Concomittant treatments -

Age (years) 66.5 y

stent (%) 98.4%

cross over from the control arm to the catheter ablation arm 1.3%

MEn (%) 62.9%

2 Patients

Patients patients with atherosclerotic renal artery stenosis and impaired renal function

Inclusion criteria -

Exclusion criteria -

indication CRI

Diabetes (%) 24.3%

baseline serum cretinine (mg/dl) 1.7 mg/dl

History of hypertension (%) 97.1%

3 Methods

Blinding open

Design Parallel groups

Centers -

Geographical area Netherlands, France

Sizes 64/76
### 4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>All cause death</td>
<td>5/64</td>
<td>6/76</td>
<td>0,99</td>
<td>[0,29; 3,41]</td>
</tr>
<tr>
<td>Heart Failure</td>
<td>-/64</td>
<td>-/76</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Stroke</td>
<td>0/64</td>
<td>1/76</td>
<td>0,40</td>
<td>[0,02; 9,89]</td>
</tr>
<tr>
<td>Worsening renal failure</td>
<td>10/64</td>
<td>16/76</td>
<td>0,76</td>
<td>[0,32; 1,78]</td>
</tr>
<tr>
<td>Number of anti-hypertensive drugs at end of study</td>
<td>-/64</td>
<td>-/76</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

### 5 References